GSK plc (NYSE:GSK) Shares Acquired by Oxbow Advisors LLC

Oxbow Advisors LLC boosted its position in GSK plc (NYSE:GSK) by 4.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,305 shares of the pharmaceutical company’s stock after purchasing an additional 5,737 shares during the period. Oxbow Advisors LLC’s holdings in GSK were worth $5,248,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Register Financial Advisors LLC acquired a new position in shares of GSK during the 1st quarter worth approximately $31,000. Richardson Financial Services Inc. purchased a new stake in shares of GSK in the fourth quarter valued at $40,000. PrairieView Partners LLC acquired a new stake in shares of GSK during the second quarter valued at $47,000. Newbridge Financial Services Group Inc. purchased a new stake in GSK during the 1st quarter worth about $49,000. Finally, Triad Wealth Partners LLC purchased a new stake in GSK during the 2nd quarter worth about $49,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Up 1.3 %

Shares of NYSE:GSK traded up $0.54 during trading on Friday, reaching $43.67. 3,763,259 shares of the stock were exchanged, compared to its average volume of 3,569,670. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92. The firm’s 50-day moving average price is $40.54 and its 200 day moving average price is $41.65. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The firm has a market cap of $90.51 billion, a price-to-earnings ratio of 15.82, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be issued a $0.3843 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a yield of 3.52%. The ex-dividend date of this dividend is Friday, August 16th. GSK’s dividend payout ratio is currently 54.71%.

Wall Street Analyst Weigh In

GSK has been the topic of several analyst reports. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group increased their price target on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. Finally, The Goldman Sachs Group began coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target on the stock. Four analysts have rated the stock with a hold rating, two have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.